In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.
The in vitro activities of DX-619, des-fluoro(6) quinolone, against 1,208 clinical isolates were examined. DX-619 was particularly potent against staphylococci, including ciprofloxacin- and methicillin-resistant strains; the MIC at which 90% of the strains tested were inhibited was 0.5 microg/ml. In addition, DX-619 was also active against gram-negative bacteria.
New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13 Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan. fujikzsl@daiichipharm.co.jp
Katsuko
K
Fujikawa
Megumi
M
Chiba
Mayumi
M
Tanaka
Kenichi
K
Sato
D000890:Anti-Infective Agents / Q000494:pharmacology*; D024841:Fluoroquinolones / Q000737:chemistry / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards
D000890:Anti-Infective Agents; D024841:Fluoroquinolones